We have a singular focus at evitria – transient antibody expression in CHO.
However, we work with a network of trusted partners, each with specific expertise. Whatever the shape of your project, evitria can support you.
Our connections enable you to shape a project to your needs, and only work with best-in-class solutions
If you are a service provider or technology licensor interested in partnering with evitria to enhance antibody development workflows, please get in touch with our business development team to explore how we can work with you in the future.
Stay up-to-date with the latest news directly in your inbox.
Subscribe to our Newsletter
Get all the latest updates, and learn about our advancements in antibody production.
Subscribe now
Discovery, expression, characterization, and CMC
Catalogue Screening, Sequencing, Recombinant expression, QC and lot release tests
Mabqi uses its proprietary phage display technology to deliver to our customers antibodies with the desired characteristics, fit for continued drug development. Mabqi offers discovery and screening services with their unique synthetic antibody library, containing >1010 diversity; this diversity is targeted to the binding “hot spots” within the antibody to ensure a high affinity binder is found. These high affinity binders are built onto Mabqi’s highly stable and high-expressing framework to provide an optimized construct suitable for further development and manufacturing. Mabqi developed proprietary processes that allow the discovery of binders overcoming traditional on-Target, off-Tumor toxicity limits, for instance using pH dependent mechanisms.
Rapid Novor helps researchers decode immunity so they can rapidly and effortlessly develop diagnostics, therapies, reagents, and treatments. Through antibody discovery and antibody sequencing services Rapid Novor have empowered thousands of researchers. The innovative next generation protein sequencing technology they have developed has the potential to unlock countless discoveries for human health. Their technology relies on mass spectrometry and advanced bioinformatics that delivers the correct sequence every time – this means you can confidently sequence and recombinantly express mAbs starting only with a small sample of protein from any species.
ProBioGen is a renowned, Berlin-based Contract Development and Manufacturing Organization (CDMO), which operates on an international scale. They offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen’s service focus is on cell line engineering, process development, and GMP manufacturing of biopharmaceutical active ingredients and vaccines for clients in biotech and pharma. ProBioGen has been operational for more than 25 years.
Biaffin is an ISO 9001:2015 certified bioanalytical service provider offering SPR Biacore services for kinetic characterization of molecular interactions. An experienced team and extensive capacities in SPR instruments enable Biaffin to start interaction studies at short notice, rapidly perform projects in parallel and obtain results in short timelines. Biaffin’s SPR Biacore services for biopharmaceutical, biosimilar and small molecule drug development comprise qualitative ranking, hit validation, lead optimization, quantitative kinetic characterization, tests for specificity and selectivity, pair-wise epitope mapping, quality control and batch to batch comparison of binding kinetics or active concentrations, customized SPR assay development and SPR assay validation according to ICH guidelines, comparability and stability studies (non-GMP and GMP), SPR assays as surrogate potency assays and ADCC studies of therapeutic antibodies binding to Fc gamma receptors (CD16, CD32, CD64) and neonatal Fc receptor (FcRn).
Antibody Analytics has experience in the full spectrum of antibody characterisation techniques, from antigen binding to functional assays. They offer standardised SPR assessments to determine binding affinities and kinetics to antigens, and antibody interacting partners such as Fc receptors, right through to cell-based functional assays to characterise antibody effector function. As well as experience in these routine characterisation assays, Antibody Analytics has experience in developing custom assay solutions and methods to interrogate the function of complex antibody-based molecules including bispecific T cell engagers, multi-specific antibodies, checkpoint inhibitors and immune cell engaging antibodies.
Genovis is an international biotech company focused on enzymes and antibodies. The unique portfolio of reagents and technologies offered by Genovis is used by industry-leading and global pharmaceutical companies in research, analytical characterization, process development and quality control. Genovis has two product portfolios; SmartEnzymes™ and Antibodies & Services. SmartEnzymes are used to analyze biological drugs and to generate new molecules with defined attributes. The speed and robustness of the analytical workflows using SmartEnzymes is offered as a service and enables customers to gain access to LC-MS quality information on candidate antibodies. Genovis is continuously launching new enzymes and product formats to meet the needs of the pharmaceutical companies and to contribute to safer and faster development of new medications.
The production of high quality, reproducible material is critical for the development of antibody-based therapeutics. The evitria-Genovis workflow combines rapid, high quality, antibody production with high-throughput mass spectrometry for greater insight and control of key quality attributes.
Download the poster to learn more.
